Matches in Nanopublications for { ?s ?p "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP621142.RATRVMb-0WVk_yKbxx8NZnunaHBqEYnnPdPkK6DIgD_ZA130_assertion description "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621142.RATRVMb-0WVk_yKbxx8NZnunaHBqEYnnPdPkK6DIgD_ZA130_provenance.
- NP622540.RAeyJ66UTGs72zktoVGfXJFKfQRHXBG1cRQe9sIE4K_SM130_assertion description "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622540.RAeyJ66UTGs72zktoVGfXJFKfQRHXBG1cRQe9sIE4K_SM130_provenance.
- NP1130027.RAawKgKzrFiyfWbFa8O-YQaO3PTUeiSEUfF5preYi0kzA130_assertion description "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1130027.RAawKgKzrFiyfWbFa8O-YQaO3PTUeiSEUfF5preYi0kzA130_provenance.
- NP1130033.RAYOjbU3W-fM3_ZAcimGm9euBTWxPqC2o7FENju1yRcps130_assertion description "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1130033.RAYOjbU3W-fM3_ZAcimGm9euBTWxPqC2o7FENju1yRcps130_provenance.
- NP624992.RAk5CbvMAZzLTCvgkdro9NNg52E-31753-pR06-3iQyDw130_assertion description "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624992.RAk5CbvMAZzLTCvgkdro9NNg52E-31753-pR06-3iQyDw130_provenance.
- NP623854.RA9DR07yIqPbjnImX66qZpiZZF8hMndEZJrIYCCh8HzoE130_assertion description "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623854.RA9DR07yIqPbjnImX66qZpiZZF8hMndEZJrIYCCh8HzoE130_provenance.
- NP1130032.RAIcDgnorGd66y2EALYpTyzF3JY65v38yyw0ntBcCN_tg130_assertion description "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1130032.RAIcDgnorGd66y2EALYpTyzF3JY65v38yyw0ntBcCN_tg130_provenance.
- NP1130028.RA8r9raw0VEH7hkz2DULx_xYtXDcQ6ydUTUnfenUXtmb0130_assertion description "[Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1130028.RA8r9raw0VEH7hkz2DULx_xYtXDcQ6ydUTUnfenUXtmb0130_provenance.